A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants

In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.
In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):
Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.
The main questions researchers want to answer are:
* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.
Each participant will be in the study for about 22 weeks.

Start Date02 Jan 2025

Sponsor / Collaborator

Biogen, Inc.

NCT06044337

/ Enrolling by invitationPhase 3

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301.
The main objective of the study is to learn more about the long-term safety of litifilimab.
The main question researchers want to answer is:
- How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are unwanted health problems that may or may not be caused by the study drug.
Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab.
The study will be done as follows:
* The last visit of parent study 230LE301 will be the first visit of study 230LE305.
* All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug.
* Globally, the treatment period will last up to 104 weeks, or 2 years. For participants in the United States, the treatment period may last up to 260 weeks, or 5 years
* There will be a follow-up safety period that lasts up to 24 weeks.
* Globally, participants will have up to 27 study visits during the treatment period. In the US, participants will have up to 66 study visits.
* Globally, the total study duration for participants will be up to 128 weeks. In the US, the total study duration will be up to 284 weeks .

Start Date03 Oct 2023

Sponsor / Collaborator

Biogen, Inc.

NCT05531565

/ RecruitingPhase 2/3

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms and signs of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
The main questions researchers want to answer are:
* How many participants have a score of 0 or 1 on the CLA-IGA-R looking at skin redness after treatment?
* How many participants have their skin disease activity go down by at least 70% as measured by CLASI?
Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and CLE have on the quality of life of participants using a group of questionnaires.
The study will be split into 2 parts - Part A and Part B. Both parts will be done as follows:
* After screening, participants will be randomized to receive either litifilimab or placebo for the 1st treatment period. A placebo looks like the study drug but contains no real medicine.
* Participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks.
* The 1st treatment period will be double blinded which means neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo.
* This double blinded treatment period will last 24 weeks, after which the 2nd treatment period will begin.
* During the 2nd treatment period, all participants will receive litifilimab for 28 weeks.
* After completing treatment in this study, participants that qualify will be given the choice to join the Long-Term Extension study, 230LE305. If they do not, they will move into a follow-up safety period that will last up to 24 weeks.
* The total study duration for participants will be up to 80 weeks.

Start Date13 Sep 2022

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Litifilimab

100 Translational Medicine associated with Litifilimab

100 Patents (Medical) associated with Litifilimab

Literatures (Medical) associated with Litifilimab

01 Jan 2026·The Journal of clinical and aesthetic dermatology

What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.

Review

Author: Childs, Beth A ; Merola, Joseph F

OBJECTIVE:

We aim to review current treatment strategies for cutaneous lupus erythematosus (CLE) and highlight emerging therapies, evolving outcome measures, and practical considerations that may inform future management of this clinically heterogeneous disease.

METHODS:

We conducted a narrative review of the literature using PubMed to identify relevant clinical trials, observational studies, and mechanistic investigations related to CLE treatment. Emphasis was placed on studies published within the past 15 years. Expert opinion from dermatology and rheumatology was incorporated to contextualize evolving therapies and their application in clinical practice.

RESULTS:

Current management of CLE follows a stepwise framework, with antimalarials and immunosuppressants forming the foundation of systemic therapy. However, many patients experience refractory disease, especially in chronic or hypertrophic subtypes. Advances in the understanding of CLE pathogenesis have led to the development of targeted biologics and small molecule agents that modulate Type I interferon signaling, B- and T-cell activation, and inflammatory cytokine pathways. Novel tools such as Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) and the Investigator Global Assessment for Cutaneous Lupus (CLA-IGA-R) are being validated to standardize disease assessment, while RNA tape sampling and real-world electronic health record (EHR)-based algorithms are enhancing research precision. Emerging therapies, such as belimumab, anifrolumab, litifilimab, deucravacitinib, and enpatoran, demonstrate promise in both clinical trials and real-world settings.

LIMITATIONS:

As a narrative review, this study is limited by the lack of systematic inclusion criteria and formal quality assessment of individual studies.

CONCLUSION:

Ongoing therapeutic innovation, guided by mechanistic insights and strengthened by the development of standardized outcome measures, is transforming the CLE landscape and advancing the goal of precision-based, durable disease control.

01 Dec 2025·Arthritis & Rheumatology

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Article

Author: Furie, Richard ; Milliman, Eric ; Franchimont, Nathalie ; Ferber, Kyle ; Werth, Victoria P. ; Barbey, Catherine ; Lahoud, Youmna ; Zoghbi, Jad ; Brown, Roland

Objective:

The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Methods:

Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received litifilimab (at 50 mg, 150 mg, or 450 mg) or a placebo were included. IFN gene signature (IFNGS) scores were assessed from whole‐blood samples using a 22‐gene panel in 120 and 131 participants (parts A and B, respectively). IFNα and other IFN‐regulated cytokine concentrations were measured in serum in 112 and 131 participants (parts A and B, respectively).

Results:

Most participants were IFNGS‐high at baseline (79–91%), and no baseline IFNGS‐low participant results were reported. In IFNGS‐high participants, litifilimab induced rapid, significant (nominal P < 0.05), and sustained reductions in IFNGS scores and IFNα concentrations versus a placebo for litifilimab at 450 mg in part A and for litifilimab at 150 mg and 450 mg in part B. In part A, IFNα reductions with litifilimab were correlated with clinical response measures. In part B, dose‐response relationships for IFNGS score and IFNα concentration were observed, similar to those for disease activity measured with the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI‐A) score.

Conclusion:

Administration of litifilimab resulted in reductions in both IFNGS scores and IFNα concentrations, pharmacodynamic effects that correlated with clinical responses. These findings support the mechanism of action of litifilimab and its continued evaluation in larger studies of patients with SLE or CLE.image

01 Jul 2025·CPT-Pharmacometrics & Systems Pharmacology

An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus

Article

Author: Volkova, Alina ; Tettamanti, Florencia ; Ugolkov, Yaroslav ; Kimko, Holly ; Tang, Weifeng ; Sokolov, Victor ; Peskov, Kirill ; Verma, Meghna

ABSTRACT:

Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).

News (Medical) associated with Litifilimab

06 Feb 2026

·www.biospace.com

Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline

iStock, wildpixel With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth. Biogen is not growing right now, but the company has established a “bridge to growth,” with an emphasis on a slew of Phase 3 readouts to come in the next few years and a careful hunt for acquisitions. “To really return to growth, I think there’s two things that really need to happen. One is we do need to start seeing the positive Phase 3 results come out and the launch of products,” CEO Chris Viehbacher said on the company’s fourth quarter earnings call on Friday. “The other of course, is [business development], and we continue to look for potential acquisition opportunities.” On the first point, Biogen is currently running 10 Phase III trials, which could one day turn into approved products. Viehbacher in particular pointed to litifilimab, which is due for mid- and late-stage readouts in two types of lupus this year. The first, a Phase 2 test for cutaneous lupus erythematosus, is expected around the end of the first quarter and the second, the late-phase systemic lupus erythematosus trial, will arrive in the fourth quarter. That product could launch in 2028, the CEO predicted. On business development, Biogen is conducting a careful search for companies in the $5 billion to $6 billion range in the post-Phase 3 results stage—a goal that has not changed in recent quarters. “The reality is that it’s hard to find things that actually generate value for our shareholders,” Viehbacher explained. “There are certainly companies out there, but we haven’t found one that we can acquire for a price that we think makes sense for our shareholders. But we continue to look. We are looking every day out there in the marketplace.” So, for now, the existing late-stage pipeline is Biogen’s future. “We have some pretty high conviction in our late-stage pipeline. Now, nothing is ever given in research and development, as we all know,” Viehbacher said. “But you know, 10 Phase 3 programs, that’s a real achievement from over the past year.” At the end of 2024, the company only had litifilimab in that advanced a stage. Since then, they have added zorevunersen for Dravet syndrome, with a Phase III read out expected in mid-year 2027, and felzartamab for antibody-mediated rejection, which will also offer late-stage data in mid-2027. “I think we’ve been able to really, again, create that bridge to growth. We’re generating cash, we’re generating profits, and we’re investing significantly in our growth brands,” Viehbacher said. Under Pressure The decline of growth comes as Biogen’s multiple sclerosis portfolio faces generic pressure around the world. This segment showed some “resilience,” according to CFO Robin Kramer, with $9.9 billion in revenue generated in 2025—a 2% increase over the year prior. Generic erosion began for Tecfidera in 2025, and in 2026 the product will face the full weight of that pressure in Europe. A biosimilar of Tysabri entered the market at the end of the year as well, Viehbacher noted. The CEO is confident that Biogen can maintain the brand for a little while longer despite this new entrant. “There’s a limited number of physicians who are very strong believers in the importance of Tysabri so that’s what we’re going to rely on,” Viehbacher said. The growth products, including Alzheimer’s disease therapy Leqembi and post-partum depression drug Zurzuvae, did bring in $3.3 billion for 2025, a 19% increase over the previous year. This helped offset the declining MS portfolio. Leqembi, which has been a slow and steady launch for Biogen, showed some strength in the fourth quarter with sales of $134 million, a 54% increase year-over-year.

Phase 3Phase 2

04 Feb 2026

·www.pharmaceutical-technology.com

FDA grants breakthrough status to Biogen’s litifilimab for CLE

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin condition. This designation aims to expedite the development and review of medicines for serious conditions. The FDA based its decision on comprehensive data, including findings from the Phase II LILAC study. Results from this trial indicated that litifilimab reduced skin disease activity in patients with CLE compared to placebo. Currently, treatment for CLE relies on antimalarials, immunosuppressants and topical steroids. While these therapies alleviate symptoms, they do not modify disease progression. The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027. Discovered and developed by Biogen scientists, litifilimab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2). It is being investigated for both CLE and systemic lupus erythematosus (SLE). Litifilimab remains an investigational product pending regulatory approval, with efficacy and safety yet to be established. Biogen development executive vice-president and head Priya Singhal said: “The FDA grants breakthrough therapy designation to programmes based on the seriousness of the condition and the potential of the therapeutic candidate to provide substantial improvements over available therapies. “The FDA’s designation reinforces Biogen’s belief that litifilimab could be a first-in-class therapy targeting BDCA2 for cutaneous lupus erythematosus. This designation is a significant milestone for litifilimab as we advance the ongoing AMETHYST Phase III study, with the goal of bringing a new potential therapeutic option to the millions of people living with CLE.” In December 2025, Biogen received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment for moderate or severe postpartum depression (PPD) in women. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultBreakthrough TherapyPriority Review

03 Feb 2026

·www.fiercepharma.com

FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision

The FDA has rejected AstraZeneca's subcutaneous version of lupus treatment Saphnelo, but the company is moving quickly to address the regulator's concerns. AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo.The FDA has sent the British drugmaker a complete response letter, rejecting its application that would allow patients to self-administer the monoclonal antibody by way of a prefilled pen, the drugmaker said in a Feb. 3 press release. While AZ did not specify the reason for the rejection, it did say that it has provided information the regulator requested and is “committed to working with the FDA to progress the application as quickly as possible.”Even with the CRL, the company said it still expects a decision on its updated Saphnelo SC application in the first half of this year.The rejection comes after the European Medicines Agency signed off on the prefilled pen in December. The advancement gives patients a convenient alternative to traveling to a doctor's office for infusions every four weeks.It also comes after AZ strengthened its case for approval last month, presenting results from a trial that showed Saphnelo SC provided a statistically significant and clinically meaningful reduction in disease activity compared with placebo, with an efficacy and safety profile consistent with its intravenous version of Saphnelo, the company said. The study also showed that the treatment helped patients reduce their use of oral corticosteroids.There was little reaction in the market to the setback as AZ’s share price increased by less than 1% on Tuesday morning. The FDA originally approved Saphnelo in 2021 as the first new treatment in a decade for systemic lupus erythematosus (SLE) and a challenger to GSK’s Benlysta. The U.K. rival gained an FDA nod for its subcutaneous version of Benlysta in 2017.GSK's BlyS inhibitor generated sales of 2.7 billion pounds sterling ($3.7 billion) in the first nine months of 2025, compared with $483 million for Saphnelo in the same period. GSK’s sales of Benlysta have also been impacted positively by label expansions starting in 2020 to treat lupus nephritis. More than 3.4 million people in the world have SLE. It primarily affects women, causing pain, rashes, fatigue, swelling in joints and fevers. In Europe, people with SLE have a two to three times increased risk of death compared to the overall population, AZ has said. Oral corticosteroids provide relief but do not target the underlying drivers of the disorder. Meanwhile, Spherix Global Insights analysts note that the lupus treatment landscape is “poised for evolution,” citing Biogen’s experimental litifilimab as an “especially strong competitor” to Benlysta and Saphnelo.AZ gained worldwide rights to Saphnelo in a 2004 licensing and collaboration agreement with Medarex, which was acquired by Bristol Myers Squibb in 2009. Under the agreement, which was updated last year, AstraZeneca pays BMS a mid-teens royalty on U.S. sales.

Drug ApprovalClinical ResultLicense out/inAcquisitionPhase 3

100 Deals associated with Litifilimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lupus Erythematosus, Discoid	Phase 3	United States	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	China	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Japan	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Argentina	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Belgium	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Brazil	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Bulgaria	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Canada	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Chile	Biogen Idec Research Ltd.	21 Feb 2024
Lupus Erythematosus, Discoid	Phase 3	Colombia	Biogen Idec Research Ltd.	21 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02847598 (LILAC \| LILAC study, CTgov)	Phase 2	Lupus Erythematosus, Cutaneous \| Systemic Lupus Erythematosus \| Lupus Erythematosus, Discoid	264	Placebo (Part A: Placebo)	vrnujhwjhl(dtbgjvqchy) = bquogceogm ueiedtsmwa (dstopmacje, 10.3) View more	-	15 May 2023
				BIIB059 (litifilimab) (Part A: BIIB059 450 mg)	vrnujhwjhl(dtbgjvqchy) = zsifhngqal ueiedtsmwa (dstopmacje, 8.7) View more
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Systemic Lupus Erythematosus BDCA2	132	Litifilimab 450 mg	nwftljwuud(astkwmxtfv): P-Value = 0.04 View more	Positive	08 Sep 2022
				Placebo
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Lupus Erythematosus, Cutaneous	132	Litifilimab 50 mg	ldidhlocox(wzjosghzue) = Litifilimab was associated with one case of herpes zoster infection tdicijjxsz (prmdnftkhc ) View more	Positive	28 Jul 2022
				Litifilimab 150 mg
NCT02847598 (LILAC, EULAR2022)	Phase 2	Systemic Lupus Erythematosus anti-nuclear antibodies \| anti-double-stranded DNA antibodies	-	BIIB059 450 mg	tufhqgkikp(kexeninuct) = rkoxgburem ewbbhtuxij (kdamozinkw ) View more	Positive	01 Jun 2022
				Placebo	tufhqgkikp(kexeninuct) = nhltwqgmpi ewbbhtuxij (kdamozinkw ) View more
NCT02847598 (LILAC study, EULAR2022)	Phase 2	Lupus Erythematosus, Cutaneous BDCA2	-	BIIB059	eyucititlk(pratxopggl) = swlykzziec tvufifeqqz (ethmleeuzr ) View more	Positive	01 Jun 2022
NCT02847598 (LILAC, ACR2020) Manual	Phase 2	Systemic Lupus Erythematosus	120	BIIB059	lvjtugnywk(riptvwljdj) = vlxranidtr aluzcdiswz (txxgdzbewc, 1.2) View more	Positive	07 Nov 2020
				Placebo	lvjtugnywk(riptvwljdj) = tedngzjvga aluzcdiswz (txxgdzbewc, 1.3) View more
NCT02847598 (LILAC, EULAR2020)	Phase 2	Lupus Erythematosus, Cutaneous	132	BIIB059 50 mg	gkukdurbbd(lmsnxiqbtq) = 62 (62.6%) 80 (60.6%) jstwcwbfbl (cutdxagvhj ) View more	Positive	03 Jun 2020
				BIIB059 150 mg
NCT02847598 (Pubmed \| J Pharmacokinet Pharmacodyn)	Phase 2	Lupus Erythematosus, Cutaneous	264	BIIB059	ecxjcvsdmu(kujmkyypqb) = xqurxxrfal riodvffrik (unmoezgvnn ) View more	-	01 Jun 2020
NCT02106897 (Pubmed \| J Clin Invest) Manual	Phase 1	Eczema \| Systemic Lupus Erythematosus	54	BIIB059	dfeovfbrmo(jxfmfdnaoy) = besbbzxuwx etilqmuklj (dotzvpxrso ) View more	Positive	01 Mar 2019
				Placebo	dfeovfbrmo(jxfmfdnaoy) = ggljwmglio etilqmuklj (dotzvpxrso ) View more
NCT02106897 (EULAR2018)	Phase 1	BDCA2 on pDC	-	BIIB059 20 mg/kg IV	xtbwlzzbbu(lqoznkyzxg) = aknclpziar vovzdwwlvx (bumaxwwizn ) View more	-	13 Jun 2018
				BIIB059 20, 50 or 150 mg SC	hozqryzxgy(wwxglxsoqa) = kcvhouilrf jrjhtygnuk (wzbnqtzgjz ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis